Related references
Note: Only part of the references are listed.Myeloid Cell-Derived Arginase in Cancer Immune Response
Tomasz M. Grzywa et al.
FRONTIERS IN IMMUNOLOGY (2020)
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors
Kuo-Ching Mei et al.
ACS NANO (2020)
Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer
Sunil Singhal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence
Chanyoung Song et al.
NATURE COMMUNICATIONS (2019)
Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy
Thanh Loc Nguyen et al.
ADVANCED MATERIALS (2019)
Recent progress on mitochondrial targeted cancer therapy based on inorganic nanomaterials
Z. Xu et al.
MATERIALS TODAY CHEMISTRY (2019)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona
Manuel Tonigold et al.
NATURE NANOTECHNOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Winson S. Ho et al.
NATURE COMMUNICATIONS (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Myeloid suppressor cells in cancer and autoimmunity
Antonio Sica et al.
JOURNAL OF AUTOIMMUNITY (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu et al.
NATURE COMMUNICATIONS (2017)
Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency
Miao Kong et al.
THERANOSTICS (2017)
All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages
Qian Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis
Jin-Xuan Fan et al.
BIOMATERIALS (2017)
A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem
Jing-Jing Hu et al.
BIOMATERIALS (2017)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers
Susanne Schoettler et al.
NATURE NANOTECHNOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Advances in Peptide Functionalization on Mesoporous Silica Nanoparticles for Controlled Drug Release
Jing-Jing Hu et al.
SMALL (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The role of myeloid cells in cancer therapies
Camilla Engblom et al.
NATURE REVIEWS CANCER (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
Kibem Kim et al.
Journal for ImmunoTherapy of Cancer (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
Melanie Bruchard et al.
NATURE MEDICINE (2013)
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface
Anna Salvati et al.
NATURE NANOTECHNOLOGY (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Evolution of end points for cancer immunotherapy trials
A. Hoos
ANNALS OF ONCOLOGY (2012)
Biomolecular coronas provide the biological identity of nanosized materials
Marco P. Monopoli et al.
NATURE NANOTECHNOLOGY (2012)
Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies
L. Apetoh et al.
CURRENT MOLECULAR MEDICINE (2011)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Vaccine Adjuvants: Putting Innate Immunity to Work
Robert L. Coffman et al.
IMMUNITY (2010)
The Inflammasomes: Guardians of the Body
Fablo Martinon et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
Hanh K. Le et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
Xuefang Cao et al.
IMMUNITY (2007)
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
B Almand et al.
JOURNAL OF IMMUNOLOGY (2001)